A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy
- 1st Edition - March 15, 2021
- Imprint: Academic Press
- Editor: Mariappan Rajan
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 9 9 8 5 - 5
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 4 4 8 4 - 5
A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy examines drug carrier development for controlled, targeted, pH and stimuli responsive drug releases for tuberculo… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteA Mechanistic Approach to Medicines for Tuberculosis Nanotherapy examines drug carrier development for controlled, targeted, pH and stimuli responsive drug releases for tuberculosis. The book provides in-depth information about mycobacterium tuberculosis, tuberculosis formation, and synthetic procedures for carrier synthesis, characterizations and mechanistic approaches. Key topics include the properties and functions of nanomedicines and how they might be applied for clinical diagnosis and treatment. Emphasis is placed on the basic fundamentals, biomaterial formulations, design principles, fabrication techniques, and transitioning bench-to-bed clinical applications.
This book is useful for new researchers who focus on nanomedicine, stem cell therapy and bone tissue engineering. In addition, it introduces experienced researchers and clinicians to key trends, thus increasing their knowledge in drug discovery for tuberculosis and nanomedicine.
- Features the most notable uses of drug for tuberculosis treatment, including novel advances in materials
- Assesses new agents and chemical compounds against tuberculosis
- Examines the interaction of new technologies to discover ways to treat tuberculosis more effectively and efficiently
Medical researchers, engineers, postdoc students, medical staff, and those in pharmaceutical companies
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter 1: Basics of tuberculosis disease and principles of treatment and their effects
- Abstract
- 1: Introduction
- 2: Host response to Mtb infection
- 3: Role of innate immune cells against Mtb infection
- 4: Immune factors involved in Mtb recognition
- 5: Cytokines role in TB infection
- 6: Mtb infection and the effector mechanism of the immune system
- 7: Adaptive immune response against TB infection
- 8: Immune evasion strategy by Mycobacterium tuberculosis
- 9: Treatment for tuberculosis infection and side effects
- 10: Drug-resistant TB
- 11: TB diagnosis
- 12: Diagnosis of latent TB infection
- 13: Conclusion
- Chapter 2: The pulmonary administration route: Advantages and challenges
- Abstract
- Acknowledgment
- 1: Introduction
- 2: Pulmonary drug delivery system (PDDS)
- 3: Pulmonary drug administration
- 4: Advantages of the pulmonary administration route
- 5: Current advances in pulmonary drug delivery
- 6: Factors affecting pulmonary drug delivery
- 7: Conclusion
- Chapter 3: Approaches toward designing nanocarriers for tuberculosis drug delivery
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Drug treatment and its current defects
- 3: Nanomaterial-based drug delivery of antitubercular drugs
- 4: Metal nanoparticles
- 5: Mesoporous silica nanoparticles
- 6: Liposomes
- 7: Polymers
- 8: Implant
- 9: Carbon nanotubes
- 10: Quantum dots
- 11: Active targeting treatment for TB
- 12: Route of administration of antitubercular drug-loaded nanomaterials
- 13: Conclusion
- Chapter 4: MoS2-based nanostructures for biomedical applications and carbon nanomaterials in TB treatment
- Abstract
- Acknowledgments
- 1: Introduction: MoS2 nanomaterials
- 2: Tuberculosis treatment using nanomaterials
- 3: Knowledge gaps and future research perspectives
- Chapter 5: pH, thermo- and stimuli-responsive nanotherapy for tuberculosis
- Abstract
- Acknowledgment
- 1: Introduction
- 2: pH-responsive antituberculosis drug delivery
- 3: Enzyme-responsive antituberculosis drug delivery
- 4: Redox-responsive antituberculosis drug delivery
- 5: Hypoxia-responsive antituberculosis drug delivery
- 6: Exogenous stimuli-responsive nanotherapy
- 7: Thermal-responsive antituberculosis drug delivery
- 8: Ultrasound-responsive antituberculosis drug delivery
- 9: Magnetic field-responsive antituberculosis drug delivery
- 10: Light-responsive antituberculosis drug delivery
- 11: Electric field-responsive antituberculosis drug delivery
- 12: Conclusion
- Chapter 6: Nanotheranostic management of drug-resistant tuberculosis
- Abstract
- Conflict of interest
- 1: Introduction
- 2: History of tuberculosis
- 3: Treatment of tuberculosis
- 4: Multidrug-resistant tuberculosis
- 5: Advancements in TB treatment strategies
- 6: Nanotechnology and nanotheranostics in TB management
- 7: Nanotheranostics—A new approach to combat multidrug-resistant TB
- 8: Summary and conclusion
- Chapter 7: Nanotherapeutic platforms for osteoarticular tuberculosis
- Abstract
- Acknowledgments
- 1: Introduction
- 2: Osteoarticular tuberculosis
- 3: Conventional therapies
- 4: Nanotherapeutics and material-based targeted therapy
- 5: Conclusions
- 6: Summary and future perspectives
- Chapter 8: Current approach of stem cell medicine in drug-resistant tuberculosis
- Abstract
- 1: Introduction
- 2: Classification of stem cells
- 3: What is multidrug-resistant tuberculosis?
- 4: Mechanism of multidrug resistance
- 5: Role of stem cell therapy for treatment of multidrug-resistant tuberculosis
- 6: Conclusion
- Chapter 9: Adjuvant nanoformulations for tuberculosis vaccine delivery
- Abstract
- 1: Introduction
- 2: Salient features of adjuvants
- 3: What is an adjuvant?
- 4: The need to develop new adjuvants
- 5: Nano- and microscale biomaterials as vaccine adjuvants and carrier vehicles
- 6: Lipid-based adjuvants
- 7: Molecular adjuvants
- 8: Promising adjuvants in clinical trials
- 9: Balancing immune response using adjuvants
- 10: Recent advancements in TB vaccine development
- 11: Conclusion and future prospects
- Chapter 10: Potential targets in quest for new antitubercular drugs: Implications of computational approaches for end-TB strategy
- Abstract
- Conflict of interest
- 1: Introduction
- 2: Drug targets in M. tuberculosis
- 3: New antitubercular agents with potential targets: Why is this essential?
- 4: Antitubercular drugs design using computational tools
- 5: Databases for antitubercular drugs discovery
- 6: Conclusion and future perspectives
- Chapter 11: Photodynamic therapy-based tuberculosis treatment
- Abstract
- 1: Introduction
- 2: Tuberculosis (TB)
- 3: Photodynamic therapy (PDT)
- 4: Tuberculosis and antimicrobial photoinactivation (aPDI)
- 5: Limitations of aPDI versus antibiotics
- 6: Enhancing and optimizing the efficacy of aPDI
- 7: Conclusions
- Chapter 12: Clinical perspectives of nanotherapy in tuberculosis treatment
- Abstract
- 1: Introduction
- 2: Nanomedicine and its clinical perspective in tuberculosis
- 3: Newer targets of MDR TB and future perspectives
- 4: Nanovaccines for TB
- 5: Potential hazards of nanoparticles
- 6: Major obstacles to nanoparticle technology
- 7: Conclusion and future directions
- Index
- Edition: 1
- Published: March 15, 2021
- No. of pages (Paperback): 326
- No. of pages (eBook): 326
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128199855
- eBook ISBN: 9780128244845
MR
Mariappan Rajan
Mariappan Rajan is currently working as an Assistant Professor in the Department of Natural Products Chemistry, School of Chemistry, Madurai Kamaraj University, India. He is an experienced researcher and is mainly interested in the development of biodegradable polymeric nanocarrier systems, nanogels, nanoparticles, nanocomposite scaffolds, bio-ceramic materials and mineral substituted scaffold for Tissue engineering, Drug Delivery and Wound Dressing applications.
Affiliations and expertise
Assistant Professor, Department of Natural Products Chemistry, School of Chemistry, Madurai Kamaraj University, IndiaRead A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy on ScienceDirect